IVEAcare, an early-stage medical device company, has named a new CEO after closing on $27 million in funding.
The Roseville company focuses on neuromodulation therapy, which sends targeted electrical impulses to specific areas of the body to treat nervous system problems. It was spun out of Nuxcel, a medical device accelerator that previously helped launch two other neuromodulation-technology startups: ShiraTronics, which is developing therapies to treat migraine headaches, and AvivoMed, focused on chronic conditions.
Newly appointed CEO and president Todd Kerkow has three decades of experience in the medical device industry at companies such as Boston Scientific, Guidant, Cardionomic and Cameron Health. Prior to iVEAcare, Kerkow served as chief operating officer at Nuxcel.
The funding will be used to innovate and deliver neuromodulation therapy to patients and clinicians, Kerkow said in a statement.
Vensana Capital led the funding round in the Roseville company, joined by Treo Ventures, Hatteras Venture Partners, and an undisclosed partner.
